检索结果-南通市图书馆

boron neutron capture therapy for malignant melanoma： first clinical case report in China

在线全文

学校读者我要写书评

暂无评论

Chinese Journal of Cancer Research 2016年第6期28卷 634-640页

作者： Zhong Yong Zewen Song Yongmao Zhou Tong Liu Zizhu Zhang Yanzhong Zhao Yang Chen Congjun Jin Xiang Chen Jianyun Lu Rui Han Pengzhou Li Xulong Sun Guohui Wang Guangqing Shi Shaihong Zhu Department of Nuclear Medicine the Third Xiangya Hospital of Central South University Changsha 410013 China Department of Oncology the Third Xiangya Hospital of Central South University Changsha 410013 China China Zhongyuan Engineering Corporation Beijing 100191 China Department of Nuclear Medicine China Nuclear Industry Beijing 401 Hospital Beijing 102413 China Medical Experimental Center the Third Xiangya Hospital of Central South University Changsha 410013 China Department of Dermatology Xiangya Hospital of Central South University Changsha 410008 China Department of Dermatology the Third Xiangya Hospital of Central South University Changsha 410013 China Department of Anesthesiology the Third Xiangya Hospital of Central South University Changsha 410013 China Department of General Surgery the Third Xiangya Hospital of Central South University Changsha 410013 China

A phase Ⅰ/Ⅱ clinical trial for treating malignant melanoma by boron neutron capture therapy（BNCT） was designed to evaluate whether the world＇s first in-hospital neutron irradiator（IHNI） was qualified for BNCT. In this clinical trial planning to enroll 30 patients, the first case was treated on August 19, 2014. We present the protocol of this clinical trial, the treating procedure, and the clinical outcome of this first case. Only grade 2 acute radiation injury was observed during the first four weeks after BNCT and the injury healed after treatment. No late radiation injury was found during the 24-month follow-up. Based on positron emission tomography-computed tomography（PET/CT） scan, pathological analysis and gross examination, the patient showed a complete response to BNCT,indicating that BNCT is a potent therapy against malignant melanoma and IHNI has the potential to enable the delivery of BNCT in hospitals.

关键词： In-hospital neutron irradiator boron neutron capture therapy malignant melanoma

boron neutron capture therapy for vulvar melanoma and genital extramammary Paget’s disease with curative responses

在线全文

学校读者我要写书评

暂无评论

Cancer Communications 2018年第1期38卷 400-409页

作者： Junichi Hiratsuka Nobuhiko Kamitani Ryo Tanaka Eisaku Yoden Ryuji Tokiya Minoru Suzuki Rolf F.Barth Koji Ono Department of Radiation Oncology Kawasaki Medical School577MatsushimaKurashikiOkayama 701-0192Japan Department of Dermatology Kawasaki Medical SchoolKurashikiOkayama 701-0192Japan Particle Radiation Oncology Kyoto University Research Reactor InstituteOsaka 590-0494Japan Department of Pathology The Ohio State UniversityColumbusOH 43210USA

Background:Although the most commonly recommended treatment for melanoma and extramammary Paget’s disease(EMPD)of the genital region is wide surgical excision of the lesion,the procedure is highly invasive and can lead to functional and sexual problems.Alternative treatments have been used for local control when wide local exci-sion was not feasible.Here,we describe four patients with genital malignancies who were treated with boron neutron capture therapy(BNCT).Methods:The four patients included one patient with vulvar melanoma(VM)and three with genital EMPD.They underwent BNCT at the Kyoto University Research Reactor between 2005 and 2014 using para-boronophenylalanine as the boron delivery agent.They were irradiated with an epithermal neutron beam between the curative tumor dose and the tolerable skin/mucosal doses.Results:All patients showed similar tumor and normal tissue responses following BNCT and achieved complete responses within 6 months.The most severe normal tissue response was moderate skin erosion during the first 2 months,which diminished gradually thereafter.Dysuria or contact pain persisted for 2 months and resolved com-pletely by 4 months.Conclusions:Treating VM and EMPD with BNCT resulted in complete local tumor control.Based on our clinical expe-rience,we conclude that BNCT is a promising treatment for primary VM and EMPD of the genital region.

关键词： boron neutron capture therapy Vulvar melanoma Extramammary Paget’s disease Penis Vulva

boron neutron capture therapy: Current status and future perspectives

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Cancer Communications 2020年第9期40卷 406-421页

作者： Mayya Alexandrovna Dymova Sergey Yurjevich Taskaev Vladimir Alexandrovich Richter Elena Vladimirovna Kuligina Laboratory of Biotechnology Institute of Chemical Biology and Fundamental MedicineSiberian Branch of the Russian Academy of SciencesLavrentjeva Av.8Novosibirsk 630090Russia Budker Institute of Nuclear Physics Siberian Branch of the Russian Academy of SciencesLavrentjeva Av.11Novosibirsk 630090Russia Laboratory of boron neutron capture therapy Novosibirsk State UniversityPirogova str.1Novosibirsk 630090Russia

The development of new accelerators has given a new impetus to the development of new drugs and treatment technologies using boron neutron capture therapy(BNCT).We analyzed the current status and future directions of BNCT for cancer treatment,as well as the main issues related to its introduction.This review highlights the principles of BNCT and the key milestones in its development:new boron delivery drugs and different types of charged particle accelerators are described;several important aspects of BNCT implementation are discussed.BCNT could be used alone or in combination with chemotherapy and radiotherapy,and it is evaluated in light of the outlined issues.For the speedy implementation of BCNT in medical practice,it is necessary to develop more selective boron delivery agents and to generate an epithermal neutron beamwith definite characteristics.Pharmacological companies and research laboratories should have access to accelerators for large-scale screening of new,more specific boron delivery agents.

关键词： boron compounds boron neutron capture therapy cancer treatment cancer drug delivery

Nanostructured boron agents for boron neutron capture therapy:a review of recent patents

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Medical Review

Medical Review 2023年第5期3卷 425-443页

作者： Xiyin Zhang Yusheng Lin Narayan SHosmane Yinghuai Zhu Shenzhen HEC Industrial Development Co. Ltd.ShenzhenGuangdong ProvinceChina Department of Chemistry and Biochemistry Northern Illinois UniversityDeKalbILUSA Sunshine Lake Pharma Co.Ltd No.368 Zhen'an Middle RoadDongguan 523871Guangdong ProvinceChina

boron neutron capture therapy(BNCT)is a potential radiation therapy modality for cancer,and tumortargeted stable boron-10(10B)delivery agents are an important component of BNCT.Currently,two low-molecular-weight boron-containing compounds,sodium mercaptoundecahydrocloso-dodecaborate(BSH)and boronophenylalanine(BPA),are mainly used in BNCT.Although both have suboptimal tumor selectivity,they have shown some therapeutic benefit in patients with high-grade glioma and several other tumors.To improve the efficacy of BNCT,great efforts have been devoted for the development of new boron delivery agents with better uptake and favorable pharmacokinetic profiles.This article reviews the application and research progress of boron nanomaterials as boron carriers in boron neutron capture therapy and hopes to stimulate people’s interest in nanomaterial-based delivery agents by summarizing various kinds of boron nanomaterial patents disclosed in the past decade.

关键词： boron agent boron neutron capture therapy dendrimer drug delivery nanomaterial

boron neutron capture therapy: moving towards targeted therapy for locally recurrent head and neck squamous cell carcinoma

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Military Medical Research 2020年第2期7卷 239-241页

作者： Ying Sun Department of Radiation Oncology Sun Yat-sen University Cancer CenterState Key Laboratory of Oncology in South ChinaCollaborative Innovation Center for Cancer MedicineGuangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and TherapyGuangzhou 510060China

Locally recurrent head and neck squamous cell carcinoma(HNSCC)is often unresectable,and a repeat course of radiotherapy is associated with incremental toxicities.boron neutron capture therapy(BNCT)is a novel targeted radiotherapy modality that can achieve a high dose gradient between cancerous and adjacent normal tissues.However,the relationships among the dose resulting from BNCT,tumor response to BNCT,and survival are not completely understood.Recently,a study published in Radiotherapy and Oncology investigated the efficacy of BNCT in the treatment of patients with locally recurrent HNSCC and the factors associated with favorable treatment response and survival.In this article,the findings,strengths and limitations of this study are discussed in depth,and the significance of the study and motivations for future research are highlighted.

关键词： Locally recurrent head and neck squamous cell carcinoma boron neutron capture therapy Treatment efficacy

Clinical trials for treating recurrent head and neck cancer with boron neutron capture therapy using the Tsing-Hua Open Pool Reactor

在线全文

学校读者我要写书评

暂无评论

Cancer Communications 2018年第1期38卷 393-399页

作者： Ling-Wei Wang Yen-Wan Hsueh Liu Fong-In Chou Shiang-Huei Jiang Department of Oncology Taipei Veterans General HospitalNo.201Section 2Shih-Pai RoadTaipei 11217TaiwanChina School of Medicine National Yang Ming UniversityTaipei 11217TaiwanChina Institute of Nuclear Engineering and Science National Tsing Hua UniversityHsin-ChuTaiwanChina Nuclear Science and Technology Development Center National Tsing Hua UniversityHsin-ChuTaiwanChina

Head and neck(HN)cancer is an endemic disease in Taiwan,China.Locally recurrent HN cancer after full-dose irradia-tion poses a therapeutic challenge,and boron neutron capture therapy(BNCT)may be a solution that could provide durable local control with tolerable toxicity.The Tsing-Hua Open Pool Reactor(THOR)at National Tsing-Hua University in Hsin-Chu,provides a high-quality epithermal neutron source for basic and clinical BNCT research.Our first clinical trial,entitled“A phase I/II trial of boron neutron capture therapy for recurrent head and neck cancer at THOR”,was carried out between 2010 and 2013.A total of 17 patients with 23 recurrent HN tumors who had received high-dose photon irradiation were enrolled in the study.The fructose complex of l-boronophenylalanine was used as a boron carrier,and a two-fraction BNCT treatment regimen at 28-day intervals was used for each patient.Toxicity was acceptable,and although the response rate was high(12/17),re-recurrence within or near the radiation site was common.To obtain better local control,another clinical trial entitled“A phase I/II trial of boron neutron capture therapy combined with image-guided intensity-modulated radiotherapy(IG-IMRT)for locally recurrent HN cancer”was initiated in 2014.The first administration of BNCT was performed according to our previous protocol,and IG-IMRT was initiated 28 days after BNCT.As of May 2017,seven patients have been treated with this combination.The treatment-related toxicity was similar to that previously observed with two BNCT applications.Three patients had a complete response,but locoregional recurrence was the major cause of failure despite initially good responses.Future clinical trials combining BNCT with other local or systemic treatments will be carried out for recurrent HN cancer patients at THOR.

关键词： Head and neck cancer boron neutron capture therapy Tsing-Hua Open Pool Reactor boronophenylalanine

Targeting the organelle for radiosensitization in cancer radiotherapy

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Asian Journal of Pharmaceutical Sciences 2024年第2期19卷 52-71页

作者： Xiaoyan Sun Linjie Wu Lina Du Wenhong Xu Min Han Institute of Pharmaceutics College of Pharmaceutical SciencesZhejiang UniversityHangzhou 310058China Department of Pharmaceutical Sciences Beijing Institute of Radiation MedicineBeijing 100850China Department of Radiation Oncology Key Laboratory of Cancer Prevention and InterventionThe Second Afliated HospitalCollege of MedicineZhejiang UniversityHangzhou 310058China Hangzhou Institute of Innovative Medicine Zhejiang UniversityHangzhou 310058China Jinhua Institute of Zhejiang University Jinhua 321299China National Key Laboratory of Advanced Drug Delivery and Release Systems Zhejiang UniversityHangzhou 310058China

Radiotherapy is a well-established cytotoxic therapy for local solid cancers, utilizing high-energy ionizing radiation to destroy cancer cells. However, this method has several limitations, including low radiation energy deposition, severe damage to surrounding normal cells, and high tumor resistance to radiation. Among various radiotherapy methods, boron neutron capture therapy (BNCT) has emerged as a principal approach to improve the therapeutic ratio of malignancies and reduce lethality to surrounding normal tissue, but it remains deficient in terms of insufficient boron accumulation as well as short retention time, which limits the curative effect. Recently, a series of radiosensitizers that can selectively accumulate in specific organelles of cancer cells have been developed to precisely target radiotherapy, thereby reducing side effects of normal tissue damage, overcoming radioresistance, and improving radiosensitivity. In this review, we mainly focus on the field of nanomedicine-based cancer radiotherapy and discuss the organelle-targeted radiosensitizers, specifically including nucleus, mitochondria, endoplasmic reticulum and lysosomes. Furthermore, the organelle-targeted boron carriers used in BNCT are particularly presented. Through demonstrating recent developments in organelle-targeted radiosensitization, we hope to provide insight into the design of organelle-targeted radiosensitizers for clinical cancer treatment.

关键词： Cancer radiotherapy Organelle-target Radiosensitization boron neutron capture therapy Nanomedicines

Evaluation of neutron beam characteristics for D-BNCT01 facility

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Nuclear Science and Techniques 2022年第1期33卷 131-139页

作者： Jun-Yang Chen Jian-Fei Tong Zhi-Liang Hu Xue-Fen Han Bin Tang Qian Yu Rui-Qiang Zhang Chong-Guang Zhao Jun Xu Shi-Nian Fu Bin Zhou Tian-Jiao Liang Institute of High Energy Physics Chinese Academy of Sciences(CAS)Beijing 100049China University of Chinese Academy of Sciences(UCAS) Beijing 100049China Spallation neutron Source Science Center Dongguan 523803China Guangdong-Hong Kong-Macao Joint Laboratory for neutron Scattering Science and Technology Dongguan 523803China

An accelerator-based boron neutron capture therapy(AB-BNCT)experimental facility called D-BNCT01 has been recently completed and is currently able to generate a high-intensity neutron beam for BNCTrelated research.In this study,we perform several experiments involving water phantoms to validate the Monte Carlo simulation results and analyze the neutron beam characteristics.According to our measurements,D-BNCT01 can generate a neutron flux about 1.2×10^(8)n/cm^(2)/s at the beam port using a 5 kW proton beam.Our results also show that the thermal neutron flux depth distribution inside the water phantom is in good agreement with simulations.We conclude that D-BNCT01 may be effectively employed for BNCT research.

关键词： neutron beam boron neutron capture therapy Water phantom